PRA Health Sciences Inc. (NASDAQ:PRAH) – Equities researchers at William Blair raised their Q4 2016 earnings per share estimates for PRA Health Sciences in a report issued on Monday. William Blair analyst J. Kreger now anticipates that the brokerage will post earnings of $0.64 per share for the quarter, up from their prior estimate of $0.63. William Blair also issued estimates for PRA Health Sciences’ FY2017 earnings at $2.84 EPS and FY2018 earnings at $3.31 EPS.

Other equities research analysts have also issued research reports about the stock. Jefferies Group reissued a “buy” rating and issued a $57.00 price objective on shares of PRA Health Sciences in a report on Friday, July 29th. KeyCorp reissued a “buy” rating on shares of PRA Health Sciences in a report on Friday, November 4th. TheStreet raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Monday, November 14th. Citigroup Inc. upped their price objective on shares of PRA Health Sciences from $55.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, September 22nd. Finally, Zacks Investment Research lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Thursday, August 11th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $55.86.

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/26/q4-2016-eps-estimates-for-pra-health-sciences-inc-increased-by-william-blair-prah.html.

PRA Health Sciences (NASDAQ:PRAH) opened at 55.06 on Thursday. PRA Health Sciences has a 12 month low of $35.60 and a 12 month high of $60.96. The stock has a 50 day moving average of $54.94 and a 200-day moving average of $49.68. The stock has a market cap of $3.38 billion, a P/E ratio of 42.75 and a beta of 0.61.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $0.64 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.64. PRA Health Sciences had a net margin of 4.86% and a return on equity of 21.25%. The firm had revenue of $399.80 million for the quarter, compared to the consensus estimate of $394.87 million. During the same quarter in the previous year, the firm earned $0.52 EPS. The company’s quarterly revenue was up 15.9% compared to the same quarter last year.

WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/26/q4-2016-eps-estimates-for-pra-health-sciences-inc-increased-by-william-blair-prah.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of PRAH. Acadian Asset Management LLC boosted its position in PRA Health Sciences by 93.3% in the second quarter. Acadian Asset Management LLC now owns 2,330,543 shares of the company’s stock worth $97,324,000 after buying an additional 1,125,077 shares during the last quarter. Columbia Wanger Asset Management LLC bought a new position in PRA Health Sciences during the second quarter worth approximately $46,366,000. Vanguard Group Inc. boosted its position in PRA Health Sciences by 33.6% in the second quarter. Vanguard Group Inc. now owns 3,390,193 shares of the company’s stock worth $141,575,000 after buying an additional 852,713 shares during the last quarter. Emerald Acquisition Ltd. bought a new position in PRA Health Sciences during the second quarter worth approximately $23,257,000. Finally, Samlyn Capital LLC bought a new position in PRA Health Sciences during the third quarter worth approximately $29,922,000.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

5 Day Chart for NASDAQ:PRAH

Receive News & Stock Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related stocks with our FREE daily email newsletter.